A comprehensive evaluation of the role of genetic variation in follicular lymphoma survival

BMC Medical Genetics

Volumn 15, Issue 1, 2014, Pages

  Baecklund, Fredrik ^a,b   Foo, Jia Nee ^c   Bracci, Paige ^d   Darabi, Hatef ^a   Karlsson, Robert ^a   Hjalgrim, Henrik ^e   Rosenquist, Richard ^f   Adami, Hans Olov ^a,g   Glimelius, Bengt ^a,f   Melbye, Mads ^e   Conde, Lucia ^h   Liu, Jianjun ^c   Humphreys, Keith ^a   Skibola, Christine F ^h   Smedby, Karin E ^a,b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c GENOME INSTITUTE OF SINGAPORE   (Singapore)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e STATENS SERUM INSTITUT   (Denmark)

^f UPPSALA UNIVERSITY   (Sweden)

^g HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^h UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Candidate gene study; Follicular lymphoma; Genome wide association study; Prognosis; Single nucleotide polymorphism

Indexed keywords

ABC TRANSPORTER; ABC TRANSPORTER A6; ABCA10 PROTEIN; INTERLEUKIN 8; MEMBRANE COFACTOR PROTEIN; UNCLASSIFIED DRUG; ABCA10 PROTEIN, HUMAN; ABCA6 PROTEIN, HUMAN; CD46 PROTEIN, HUMAN; IL8 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER MORTALITY; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CLINICAL EVALUATION; COHORT ANALYSIS; CONTROLLED STUDY; DENMARK; FEMALE; FOLLICULAR LYMPHOMA; FOLLICULAR LYMPHOMA INTERNATIONAL PROGNOSTIC INDEX; FOLLOW UP; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC CODE; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; META ANALYSIS (TOPIC); MULTIDRUG RESISTANCE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; SWEDEN; TUMOR GENE; UNITED STATES; ADOLESCENT; GENETICS; MIDDLE AGED; MORTALITY; SURVIVAL; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIGENS, CD46; ATP-BINDING CASSETTE TRANSPORTERS; FEMALE; GENOME-WIDE ASSOCIATION STUDY; HUMANS; INTERLEUKIN-8; LYMPHOMA, FOLLICULAR; MALE; META-ANALYSIS AS TOPIC; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; SURVIVAL ANALYSIS; YOUNG ADULT;

EID: 84908114058     PISSN: None     EISSN: 14712350     Source Type: Journal    
DOI: 10.1186/s12881-014-0113-6     Document Type: Article

References (51)

1. Freedman A. Follicular lymphoma: 2014 update on diagnosis and management. Am J Hematol 2014, 89(4):429-436. 10.1002/ajh.23674, 24687887.
2. Relander T, Johnson NA, Farinha P, Connors JM, Sehn LH, Gascoyne RD. Prognostic factors in follicular lymphoma. J Clin Oncol 2010, 28(17):2902-2913. 10.1200/JCO.2009.26.1693, 20385990.
3. Aschebrook-Kilfoy B, Zheng T, Foss F, Ma S, Han X, Lan Q, Holford T, Chen Y, Leaderer B, Rothman N, Zhang Y. Polymorphisms in immune function genes and non-Hodgkin lymphoma survival. J Cancer Surviv 2012, 6(1):102-114. 10.1007/s11764-010-0164-4, 22113576.
4. Berglund M, Enblad G, Thunberg U. SNP rs6457327 is a predictor for overall survival in follicular lymphoma as well as survival after transformation. Blood 2011, 118(16):4489. 10.1182/blood-2011-06-362921, 22021453.
5. Carlotti E, Palumbo GA, Oldani E, Tibullo D, Salmoiraghi S, Rossi A, Golay J, Pulsoni A, Foa R, Rambaldi A. FcgammaRIIIA and FcgammaRIIA polymorphisms do not predict clinical outcome of follicular non-Hodgkin's lymphoma patients treated with sequential CHOP and rituximab. Haematologica 2007, 92(8):1127-1130. 10.3324/haematol.11288, 17650444.
6. Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colombat P, Watier H. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 2002, 99(3):754-758. 10.1182/blood.V99.3.754, 11806974.
7. Cerhan JR, Wang S, Maurer MJ, Ansell SM, Geyer SM, Cozen W, Morton LM, Davis S, Severson RK, Rothman N, Lynch CF, Wacholder S, Chanock SJ, Habermann TM, Hartge P. Prognostic significance of host immune gene polymorphisms in follicular lymphoma survival. Blood 2007, 109(12):5439-5446. 10.1182/blood-2006-11-058040, 17327408.
8. Charbonneau B, Maurer MJ, Fredericksen ZS, Zent CS, Link BK, Novak AJ, Ansell SM, Weiner GJ, Wang AH, Witzig TE, Dogan A, Slager SL, Habermann TM, Cerhan JR. Germline variation in complement genes and event-free survival in follicular and diffuse large B-cell lymphoma. Am J Hematol 2012, 87(9):880-885. 10.1002/ajh.23273, 22718493.
9. Charbonneau B, Wang AH, Maurer MJ, Asmann YW, Zent CS, Link BK, Ansell SM, Weiner GJ, Ozsan N, Feldman AL, Witzig TE, Cunningham JM, Dogan A, Habermann TM, Slager SL, Novak AJ, Cerhan JR. CXCR5 polymorphisms in non-Hodgkin lymphoma risk and prognosis. Cancer Immunol Immunother 2013, 62(9):1475-1484. 10.1007/s00262-013-1452-4, 23812490.
10. Ghesquieres H, Cartron G, Seymour JF, Delfau-Larue MH, Offner F, Soubeyran P, Perrot A, Brice P, Bouabdallah R, Sonet A, Dupuis J, Casasnovas O, Catalano JV, Delmer A, Jardin F, Verney A, Dartigues P, Salles G. Clinical outcome of patients with follicular lymphoma receiving chemoimmunotherapy in the PRIMA study is not affected by FCGR3A and FCGR2A polymorphisms. Blood 2012, 120(13):2650-2657. 10.1182/blood-2012-05-431825, 22885164.
11. Ghielmini M, Rufibach K, Salles G, Leoncini-Franscini L, Leger-Falandry C, Cogliatti S, Fey M, Martinelli G, Stahel R, Lohri A, Ketterer N, Wernli M, Cerny T, Schmitz SF. Single agent rituximab in patients with follicular or mantle cell lymphoma: clinical and biological factors that are predictive of response and event-free survival as well as the effect of rituximab on the immune system: a study of the Swiss Group for Clinical Cancer Research (SAKK). Ann Oncol 2005, 16(10):1675-1682. 10.1093/annonc/mdi320, 16030029.
12. Gibson TM, Wang SS, Cerhan JR, Maurer MJ, Hartge P, Habermann TM, Davis S, Cozen W, Lynch CF, Severson RK, Rothman N, Chanock SJ, Morton LM. Inherited genetic variation and overall survival following follicular lymphoma. Am J Hematol 2012, 87(7):724-726. 10.1002/ajh.23184, 22473939.
13. Persky DO, Dornan D, Goldman BH, Braziel RM, Fisher RI, Leblanc M, Maloney DG, Press OW, Miller TP, Rimsza LM. Fc gamma receptor 3a genotype predicts overall survival in follicular lymphoma patients treated on SWOG trials with combined monoclonal antibody plus chemotherapy but not chemotherapy alone. Haematologica 2012, 97(6):937-942. 10.3324/haematol.2011.050419, 22271896.
14. Racila E, Link BK, Weng WK, Witzig TE, Ansell S, Maurer MJ, Huang J, Dahle C, Halwani A, Levy R, Weiner GJ. A polymorphism in the complement component C1qA correlates with prolonged response following rituximab therapy of follicular lymphoma. Clin Cancer Res 2008, 14(20):6697-6703. 10.1158/1078-0432.CCR-08-0745, 18927313.
15. Wang SS, Maurer MJ, Morton LM, Habermann TM, Davis S, Cozen W, Lynch CF, Severson RK, Rothman N, Chanock SJ, Hartge P, Cerhan JR. Polymorphisms in DNA repair and one-carbon metabolism genes and overall survival in diffuse large B-cell lymphoma and follicular lymphoma. Leukemia 2009, 23(3):596-602. 10.1038/leu.2008.240, 18830263.
16. Weng WK, Czerwinski D, Timmerman J, Hsu FJ, Levy R. Clinical outcome of lymphoma patients after idiotype vaccination is correlated with humoral immune response and immunoglobulin G Fc receptor genotype. J Clin Oncol 2004, 22(23):4717-4724. 10.1200/JCO.2004.06.003, 15483014.
17. Weng WK, Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 2003, 21(21):3940-3947. 10.1200/JCO.2003.05.013, 12975461.
18. Wrench D, Leighton P, Skibola CF, Conde L, Cazier JB, Matthews J, Iqbal S, Carlotti E, Bodor C, Montoto S, Calaminici M, Gribben JG, Lister TA, Fitzgibbon J. SNP rs6457327 in the HLA region on chromosome 6p is predictive of the transformation of follicular lymphoma. Blood 2011, 117(11):3147-3150. 10.1182/blood-2010-10-315382, 21233317.
19. Gribben JG. Implications of the tumor microenvironment on survival and disease response in follicular lymphoma. Curr Opin Oncol 2010, 22(5):424-430. 10.1097/CCO.0b013e32833d5938, 20679770.
20. Phan VH, Tan C, Rittau A, Xu H, McLachlan AJ, Clarke SJ. An update on ethnic differences in drug metabolism and toxicity from anti-cancer drugs. Expert Opin Drug Metab Toxicol 2011, 7(11):1395-1410. 10.1517/17425255.2011.624513, 21950349.
21. Bruhns P, Iannascoli B, England P, Mancardi DA, Fernandez N, Jorieux S, Daeron M. Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses. Blood 2009, 113(16):3716-3725. 10.1182/blood-2008-09-179754, 19018092.
22. Conde L, Halperin E, Akers NK, Brown KM, Smedby KE, Rothman N, Nieters A, Slager SL, Brooks-Wilson A, Agana L, Riby J, Liu J, Adami HO, Darabi H, Hjalgrim H, Low HQ, Humphreys K, Melbye M, Chang ET, Glimelius B, Cozen W, Davis S, Hartge P, Morton LM, Schenk M, Wang SS, Armstrong B, Kricker A, Milliken S, Purdue MP, et al. Genome-wide association study of follicular lymphoma identifies a risk locus at 6p21.32. Nat Genet 2010, 42(8):661-664. 10.1038/ng.626, 20639881.
23. Morton LM, Purdue MP, Zheng T, Wang SS, Armstrong B, Zhang Y, Menashe I, Chatterjee N, Davis S, Lan Q, Vajdic CM, Severson RK, Holford TR, Kricker A, Cerhan JR, Leaderer B, Grulich A, Yeager M, Cozen W, Hoar Zahm S, Chanock SJ, Rothman N, Hartge P. Risk of non-Hodgkin lymphoma associated with germline variation in genes that regulate the cell cycle, apoptosis, and lymphocyte development. Cancer Epidemiol Biomarkers Prev 2009, 18(4):1259-1270. 10.1158/1055-9965.EPI-08-1037, 19336552.
24. Skibola CF, Bracci PM, Halperin E, Conde L, Craig DW, Agana L, Iyadurai K, Becker N, Brooks-Wilson A, Curry JD, Spinelli JJ, Holly EA, Riby J, Zhang L, Nieters A, Smith MT, Brown B. Genetic variants at 6p21.33 are associated with susceptibility to follicular lymphoma. Nat Genet 2009, 41(8):873-875. 10.1038/ng.419, 19620980.
25. Smedby KE, Foo JN, Skibola CF, Darabi H, Conde L, Hjalgrim H, Kumar V, Chang ET, Rothman N, Cerhan JR, Brooks-Wilson AR, Rehnberg E, Irwan ID, Ryder LP, Brown PN, Bracci PM, Agana L, Riby J, Cozen W, Davis S, Hartge P, Morton LM, Severson RK, Wang SS, Slager SL, Fredericksen ZS, Novak AJ, Kay NE, Habermann TM, Armstrong B, et al. GWAS of follicular lymphoma reveals allelic heterogeneity at 6p21.32 and suggests shared genetic susceptibility with diffuse large B-cell lymphoma. PLoS Genet 2011, 7(4):e1001378. 10.1371/journal.pgen.1001378, 21533074.
26. Wang SS, Purdue MP, Cerhan JR, Zheng T, Menashe I, Armstrong BK, Lan Q, Hartge P, Kricker A, Zhang Y, Morton LM, Vajdic CM, Holford TR, Severson RK, Grulich A, Leaderer BP, Davis S, Cozen W, Yeager M, Chanock SJ, Chatterjee N, Rothman N. Common gene variants in the tumor necrosis factor (TNF) and TNF receptor superfamilies and NF-kB transcription factors and non-Hodgkin lymphoma risk. PLoS One 2009, 4(4):e5360. 10.1371/journal.pone.0005360, 19390683.
27. Smedby KE, Hjalgrim H, Melbye M, Torrang A, Rostgaard K, Munksgaard L, Adami J, Hansen M, Porwit-MacDonald A, Jensen BA, Roos G, Pedersen BB, Sundstrom C, Glimelius B, Adami HO. Ultraviolet radiation exposure and risk of malignant lymphomas. J Natl Cancer Inst 2005, 97(3):199-209. 10.1093/jnci/dji022, 15687363.
28. Jaffe E. Pathology and genetics of tumours of hematopoietic and lymphoid tissues 2001, IARC Press, International Agency for Research on Cancer, Lyon, France.
29. The Swedish Cause of Death Register, The National Board of Health and Welfare, Sweden.Available at:. Accessed May 2, 2012. In.., http://www.socialstyrelsen.se/register/dodsorsaksregistret
30. D'Amore F, Christensen BE, Brincker H, Pedersen NT, Thorling K, Hastrup J, Pedersen M, Jensen MK, Johansen P, Andersen E, Bach B, Sørensen E. Clinicopathological features and prognostic factors in extranodal non-Hodgkin lymphomas. Danish LYFO Study Group. Eur J Cancer 1991, 27(10):1201-1208. 10.1016/0277-5379(91)90081-N, 1835586.
31. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, Maller J, Sklar P, de Bakker PI, Daly MJ, Sham PC. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 2007, 81(3):559-575. 10.1086/519795, 17701901.
32. Price AL, Patterson NJ, Plenge RM, Weinblatt ME, Shadick NA, Reich D. Principal components analysis corrects for stratification in genome-wide association studies. Nat Genet 2006, 38(8):904-909. 10.1038/ng1847, 16862161.
33. Skibola CF, Bracci PM, Halperin E, Nieters A, Hubbard A, Paynter RA, Skibola DR, Agana L, Becker N, Tressler P, Forrest MS, Sankararaman S, Conde L, Holly EA, Smith MT. Polymorphisms in the estrogen receptor 1 and vitamin C and matrix metalloproteinase gene families are associated with susceptibility to lymphoma. PLoS One 2008, 3(7):e2816. 10.1371/journal.pone.0002816, 18636124.
34. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986, 7(3):177-188. 10.1016/0197-2456(86)90046-2, 3802833.
35. R: A Language and Environment for Statistical Computing 2010, R Foundation for Statistical Computing, Vienna, Austria.
36. Pruim RJ, Welch RP, Sanna S, Teslovich TM, Chines PS, Gliedt TP, Boehnke M, Abecasis GR, Willer CJ. LocusZoom: regional visualization of genome-wide association scan results. Bioinformatics 2010, 26(18):2336-2337. 10.1093/bioinformatics/btq419, 20634204.
37. Boyle AP, Hong EL, Hariharan M, Cheng Y, Schaub MA, Kasowski M, Karczewski KJ, Park J, Hitz BC, Weng S, Cherry JM, Snyder M. Annotation of functional variation in personal genomes using RegulomeDB. Genome Res 2012, 22(9):1790-1797. 10.1101/gr.137323.112, 22955989.
38. Bland JM, Altman DG. Multiple significance tests: the Bonferroni method. BMJ 1995, 310(6973):170. 10.1136/bmj.310.6973.170, 7833759.
39. Falasca M, Linton KJ. Investigational ABC transporter inhibitors. Expert Opin Investig Drugs 2012, 21(5):657-666. 10.1517/13543784.2012.679339, 22493979.
40. Yagi K, Yamamoto K, Umeda S, Abe S, Suzuki S, Onishi I, Kirimura S, Fukayama M, Arai A, Kitagawa M, Kurata M. Expression of multidrug resistance 1 gene in B-cell lymphomas: association with follicular dendritic cells. Histopathology 2013, 62(3):414-420. 10.1111/his.12035, 23339364.
41. Coleman JA, Quazi F, Molday RS. Mammalian P4-ATPases and ABC transporters and their role in phospholipid transport. Biochim Biophys Acta 2013, 1831(3):555-574. 10.1016/j.bbalip.2012.10.006, 23103747.
42. Aung T, Chapuy B, Vogel D, Wenzel D, Oppermann M, Lahmann M, Weinhage T, Menck K, Hupfeld T, Koch R, Trumper L, Wulf GG. Exosomal evasion of humoral immunotherapy in aggressive B-cell lymphoma modulated by ATP-binding cassette transporter A3. Proc Natl Acad Sci U S A 2011, 108(37):15336-15341. 10.1073/pnas.1102855108, 21873242.
43. Flicek P, Amode MR, Barrell D, Beal K, Billis K, Brent S, Carvalho-Silva D, Clapham P, Coates G, Fitzgerald S, Gil L, Giron CG, Gordon L, Hourlier T, Hunt S, Johnson N, Juettemann T, Kahari AK, Keenan S, Kulesha E, Martin FJ, Maurel T, McLaren WM, Murphy DN, Nag R, Overduin B, Pignatelli M, Pritchard B, Pritchard E, Riat HS, et al. Ensembl 2014. Nucleic Acids Res 2014, 42(Database issue):D749-755. 10.1093/nar/gkt1196, 24316576.
44. O'Brien P, Morin P, Ouellette RJ, Robichaud GA. The Pax-5 gene: a pluripotent regulator of B-cell differentiation and cancer disease. Cancer Res 2011, 71(24):7345-7350. 10.1158/0008-5472.CAN-11-1874, 22127921.
45. Vazquez-Carretero MD, Garcia-Miranda P, Calonge ML, Peral MJ, Ilundain AA. Dab1 and reelin participate in a common signal pathway that controls intestinal crypt/villus unit dynamics. Biol Cell 2014, 106(3):83-96. 10.1111/boc.201300078, 24313315.
46. Batra J, O'Mara T, Patnala R, Lose F, Clements JA. Genetic polymorphisms in the human tissue kallikrein (KLK) locus and their implication in various malignant and non-malignant diseases. Biol Chem 2012, 393(12):1365-1390. 10.1515/hsz-2012-0211, 23667899.
47. Yan J, Allendorf DJ, Li B, Yan R, Hansen R, Donev R. The role of membrane complement regulatory proteins in cancer immunotherapy. Adv Exp Med Biol 2008, 632:159-174. 19025121.
48. Wang N, Zhou R, Wang C, Guo X, Chen Z, Yang S, Li Y. -251 T/A polymorphism of the interleukin-8 gene and cancer risk: a HuGE review and meta-analysis based on 42 case-control studies. Mol Biol Rep 2012, 39(3):2831-2841. 10.1007/s11033-011-1042-5, 21681427.
49. Wang D, Sun Y, Stang P, Berlin JA, Wilcox MA, Li Q. Comparison of methods for correcting population stratification in a genome-wide association study of rheumatoid arthritis: principal-component analysis versus multidimensional scaling. BMC Proc 2009, 3(Suppl 7):S109. 10.1186/1753-6561-3-s7-s109, 20017973.
50. Pasche B, Yi N. Candidate gene association studies: successes and failures. Curr Opin Genet Dev 2010, 20(3):257-261. 10.1016/j.gde.2010.03.006, 20417090.
51. Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, Coiffier B, Fisher RI, Hagenbeek A, Zucca E, Rosen ST, Stroobants S, Lister TA, Hoppe RT, Dreyling M, Tobinai K, Vose JM, Connors JM, Federico M, Diehl V. Revised response criteria for malignant lymphoma. J Clin Oncol 2007, 25(5):579-586. 10.1200/JCO.2006.09.2403, 17242396.